Gsa Capital Partners LLP Fate Therapeutics Inc Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$3.26 - $7.08 $691,732 - $1.5 Million	212,188 Added 405.88%	264,467 $867,000
Q1 2024 May 03, 2024	BUY	$3.54 - $8.35 $32,837 - $77,454	9,276 Added 21.57%	52,279 $383,000
Q4 2023 Feb 16, 2024	SELL	$1.65 - $3.94 $347,202 - $829,078	-210,426 Reduced 83.03%	43,003 $160,000
Q3 2023 Nov 15, 2023	BUY	$2.02 - $5.04 $119,218 - $297,455	59,019 Added 30.36%	253,429 $537,000
Q2 2023 Aug 14, 2023	SELL	$4.76 - $6.59 $76,160 - $105,440	-16,000 Reduced 7.6%	194,410 $925,000
Q1 2023 May 12, 2023	BUY	$4.24 - $11.12 $644,386 - $1.69 Million	151,978 Added 260.09%	210,410 $1.2 Million
Q4 2022 Feb 13, 2023	BUY	$9.86 - $23.83 $576,139 - $1.39 Million	58,432 New	58,432 $590,000

179

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $127M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.